Data as of Sep 19
| -0.05 / -1.68%|
The 2 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 6.00, with a high estimate of 11.00 and a low estimate of 1.00. The median estimate represents a +105.48% increase from the last price of 2.92.
The current consensus among 4 polled investment analysts is to Hold stock in ZIOPHARM Oncology Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.